The IMF trims its economic growth forecast again as the U.S.-China trade war continues, Brexit worries linger and inflation remains muted.Economyread more
Citigroup thinks Tesla investors hoping for a post-earnings rally later this week should scrutinize a pair of related financial metrics.Investingread more
Olive branches were extended from both China and the U.S. as the two nations are set to restart face-to-face trade negotiations after a monthlong truce.Marketsread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
New disclosures show Facebook and Amazon each spent more than $4 million on lobbying activity in the second quarter of 2019.Technologyread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
Disney can nearly double its earnings by 2024, Morgan Stanley said in a note to clients on Tuesday.Investingread more
Amazon is expected to report its second-quarter earnings on Thursday.Investingread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Canaccord Genuity's Tony Dwyer believes stocks are about to fall as much as 5% from their all-time highs.Trading Nationread more
(Compares with estimates, details on segment revenue)
Feb 19 (Reuters) - Medical device maker Medtronic Plc on Tuesday beat Wall Street estimates for quarterly profit, driven by higher sales in its surgical products unit and restorative therapies group.
Its fast-growing minimally invasive therapies business, which makes surgical instruments and endoscopy products, brought in revenue of $2.12 billion, above analysts' expectation of $2.08 billion.
The company said it expects full-year earnings to be in the range of $5.14 to $5.16 per share, up from the prior forecast of $5.10 to $5.15 per share. Analysts had expected $5.12 per share.
Medtronic also raised its 2019 forecast for organic revenue growth to 5.25 percent to 5.5 percent, but said a strong dollar would impact its full-year revenue by about $425 million to $475 million.
Revenue from its restorative therapies division, which makes medical devices and implants to treat neurological disorders and conditions affecting the spine, rose 4.2 percent to beat the average analyst estimate of $2.02 billion.
Net income attributable to Medtronic was $1.27 billion, or 94 cents per share, in the quarter ended Jan. 25, compared with a loss of $1.39 billion, or $1.03 per share, a year earlier, when it recorded a tax-related charge.
Excluding items, the company earned $1.29 per share, beating analysts' expectations of $1.24 per share, according to IBES data from Refinitiv.
Revenue rose 2.4 percent to $7.55 billion and beat analysts' estimate of $7.52 billion. (Reporting by Manogna Maddipatla and Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur)